Timing of hypertonic saline inhalation for cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 2, 2012, Pages

  Elkins, Mark ^a   Dentice, Ruth ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

SODIUM CHLORIDE;

CYSTIC FIBROSIS; DRUG ADMINISTRATION; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; MUCOCILIARY CLEARANCE; PATHOPHYSIOLOGY; REVIEW; SECRETION; SPUTUM;

ADMINISTRATION, INHALATION; CYSTIC FIBROSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MUCOCILIARY CLEARANCE; SALINE SOLUTION, HYPERTONIC; SPUTUM;

EID: 84861325392     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008816.pub2     Document Type: Review

References (69)

1. Adde FV, Borges KTL, Hatanaka ACF, Nakaie CMA, Cardieri JMA, Oliveira RC, et al. Hypertonic saline X recombinant human DNase: a randomised crossover study in 18 cystic fibrosis patients [abstract]. Journal of Cystic Fibrosis 2004;4(Suppl 1):S66.
2. Amin R, Subbarao P, Jabar A, Balkovec S, Jensen R, Kerrigan S, et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax 2010;65(5):379-83.
3. Amin R, Subbarao P, Jabar A, Balkovec S, Jensen R, Kerrigan S, et al. Inhaled hypertonic saline (7%) improves LCI in paediatric CF patients with normal lung function [abstract]. Pediatric Pulmonology 2009;44(Suppl 32):289, Abstract no: 223.
4. Ballmann M, von der Hardt H. Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis [abstract]. 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:80.
5. Ballmann M, von der Hardt H. Hyptertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. Journal of Cystic Fibrosis 2002;1(1):35-7.
6. Buonpensiero P, De Gregorio F, Sepe A, Di Pasqua A, Ferri P, Siano M, et al. Hyaluronic acid improves "pleasantness" and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis. Advances in Therapy 2010;27(11):870-8.
7. Buonpensiero P, De Gregorio F, Sepe A, Di Pasqua A, Ferri P, Siano M, et al. Hyaluronic acid improves tolerability of hypertonic saline in CF patients [abstract]. Journal of Cytsic Fibrosis 2010;9(Suppl 1):S63.
8. Buonpensiero P, De Gregorio F, Sepe A, Di Pasqua A, Ferri P, Siano M, et al. Inhaled hyaluronic acid improves pleasantness and tolerability of nebulised hypertonic saline in patients with cystic fibrosis [abstract]. Pediatric Pulmonology 2009;44(Suppl 32):243.
9. Cardinale F, Manca A, Mappa L, Tesse R, Cavallone R, Loffredo MS, et al. Effects on exhaled nitric oxide levels and lung function of ultrasonically nebulized hypertonic solution in cystic fibrosis [abstract]. European Respiratory Journal 2003;22(Suppl 45):231s.
10. Chadwick SL, Moss SJ, Bott J, Geddes DM, Alton EWFW. Effect of hypertonic saline, isotonic saline and water challenges on the airways of cystic fibrosis patients [abstract]. Thorax 1997;52(Suppl 6):A43.
11. De Cono N, Schelstraete P, Haerynck F, Van daele S, Sanders N, De Baets F. Hypertonic saline: effect on mucus rheology and spirometry [abstract]. Journal of Cystic Fibrosis 2008;7(Suppl 2):S24.
12. Donaldson SH, Bennett W, Zeman K, Knowles MR, Boucher RC. Efficacy of amiloride and hypertonic saline in cystic fibrosis [abstract]. Pediatric Pulmonology 2003;Suppl 25:251.
13. Donaldson SH, Bennett W, Zenman K, Knowles MR, Boucher RC. Efficacy of amiloride and hypertonic saline in cystic fibrosis. Pedaitric Pulmonology 2003;Suppl 25:251.
14. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. New England Journal of Medicine 2006;354(3):241-50.
15. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Online Supplement to 'Mucus clearance and lung function in cystic fibrosis with hypertonic saline' [online]. New England Journal of Medicine 2006; Vol. 354, issue 3:241-50.
16. Bye P, Elkins M, Robinson M, Moriarty C, Rose B, Harbour C, et al. Long-term inhalation of hypertonic saline in patients with cystic fibrosis- a randomised controlled trial [abstract]. Pediatric Pulmonology 2004;38(Suppl 27):329.
17. Elkins M, Robinson M, Moriarty C, Sercombe J, Rose B, Harbour C, et al. Three methods of monitoring adherence in a long-term trial in Cystic Fibrosis [abstract]. Journal of Cystic Fibrosis 2006;40(Suppl 28):268.
18. Elkins MR, Robinson M, Moriarty C, Sercombe J, Rose B, Harbour C. Three methods of monitoring adherence in the national hypertonic saline trial in cystic fibrosis [abstract]. Pediatric Pulmonology 2005;40(Suppl 28):268.
19. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. New England Journal of Medicine 2006;354(3):229-40.
20. Elkins MR, Tingpej P, Moriarty CP, Yozghatlian V, Rose BR, Harbour C, et al. Tolerability of hypertonic saline when delivered rapidly via the Eflow® rapid nebulizer in subjects with cystic fibrosis [abstract]. Pediatric Pulmonlogy 2006;41(Suppl 29):292.
21. Button BM, Riedler J, Reade T, Eng P, Robertson CF. Inhaled hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis: The three-year clinical experience [abstract]. Pediatric Pulmonology 1996;22(Suppl 13):306.
22. Eng P, Morton J, Douglass J, Riedler J, Wilson J, Robertson CF. Efficacy of short-term ultrasonically nebulised hypertonic saline in patients with cystic fibrosis [abstract]. European Respiratory Journal 1995;8(Suppl 19):510s.
23. Eng P, Morton J, Douglass J, Riedler J, Wilson J, Robertson CF. Short-term administration of ultrasonically nebulised hypertonic saline improves pulmonary function in patients with cystic fibrosis [abstract]. Australian and New Zealand Journal of Medicine 1995;25:440.
24. Eng PA, Morton J, Douglass JA, Riedler J, Wilson J, Robertson CF. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatric Pulmonology 1996;21(2):77-83. [MEDLINE: 97036562]
25. Grieve R, Thompson S, Normand C, Suri R, Bush A, Wallis C. A cost-effectiveness analysis of rhDNase in children with cystic fibrosis. International Journal of Technology Assessment in Health Care 2003;19(1):71-9.
26. Hofmann T, Senier I, Ziersch A, Geidel C, Regnis J, Lindemann H. Additive effect of amiloride and hypertonic saline on respiratory ion transport cystic fibrosis [abstract]. Proceedings of the 21st European Cystic Fibrosis Conference; 1997; Davos, Switzerland. 1997:119.
27. Kobylyansky VI, Gembitskaya TE. Study of the mucociliary and cough clearance in patients with mucoviscidosis and evaluation of hypertonic sodium chorlide solution influence on them [abstract]. European Respiratory Journal 2000;16(Suppl 31):121S.
28. Laube BI, Sharpless GJ, Kelly AE, Mogayzel PJ. Effect of hypertonic saline on mucociliary clearance in children with cystic fibrosis [abstract]. Pediatric Pulmonology 2009;44 Suppl 32:238, Abstract no: 77.
29. Button BM, Riedler J, Reade T, Eng P, Robertson CF. Inhlaed hypertonic saline as an adjunct to chest physiotherapy in cystic fibrosis; the three year clinical experience. Pediatric Pulmonology 1996;Suppl 13:306.
30. Riedler J, Reade T, Button B, Robertson CF. A pilot study of inhaled hypertonic saline to increase sputum production in adolescents with cystic fibrosis [abstract]. European Respiratory Journal 1994;7 Suppl 18:430s.
31. Riedler J, Reade T, Button B, Robertson CF. Inhaled hypertonic saline increases sputum expectoration in cystic fibrosis. Journal of Paediatrics and Child Health 1996;32(1):48-50. [MEDLINE: 97036562]
32. Robinson M, Regnis JA, Bailey DL, King M, Bautovich GJ, Bye PT. Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 1996;153(5):1503-9.
33. Robinson M, Hemming AL, Bailey DL, Mellis CM, Bautovich GJ, Bye PTP. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis [abstract]. American Journal of Respiratory and Critical Care Medicine 1996;154(Suppl):A70.
34. Robinson M, Hemming AL, Regnis JA, Wong AG, Bailey DL, Bautovich GJ, et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997;52(10):900-3. [MEDLINE: 98068190]
35. Robinson M, Parsons S, Hemming A, Bautovich G, Mellis CM, Bye PTP. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis [abstract]. Australian and New Zealand Journal of Medicine 1997;27:258.
36. Robinson M, Daviskas E, Eberl S, Baker J, Anderson SD, Bye PT. Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis [abstract]. Pediatric Pulmonology 1998;Suppl 17:280. [MEDLINE: 97036562]
37. Robinson M, Daviskas E, Eberl S, Baker J, Chan HK, Anderson SD, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. European Respiratory Journal 1999;14(3):678-85.
38. Robinson M, Daviskas E, Eberl S, Baker J, Chan HK, Anderson SD, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study [abstract]. Pediatric Pulmonology 2000;29(6):484.
39. Suri R, Grieve R, Normand C, Metcalfe C, Thompson S, Wallis C, et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis. Thorax 2002;57(10):841-6.
40. Suri R, Grieve R, Normand C, Metcalfe C, Thompson S, Wallis C, et al. Effects of hypertonic saline, alternate day and daily rhDNase on healthcare use, costs and outcomes in children with cystic fibrosis [abstract]. Thorax 2001;56(Suppl 3):iii84.
41. Suri R, Marshall LJ, Wallis C, Metcalfe C, Bush A, Shute JK. Effects of recombinant human DNase and hypertonic saline on airway inflammation in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2002;166(3):352-5.
42. Suri R, Metcalfe C, Lees B, Flather M, Normand C, Thompson S, et al. A cross-over comparative study of hypertonic saline alternate day and daily rhDNase in children with cystic fibrosis [abstract]. Thorax 2000;55:A75.
43. Suri R, Metcalfe C, Lees B, Grieve R, Flather M, Normand C, et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 2001;358(9290):1316-21.
44. Suri R, Metcalfe C, Wallis C, Bush A. Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis. Pediatric Pulmonology 2004;37(4):305-10.
45. Suri R, Wallis C, Bush A. In vivo use of hypertonic saline in CF [abstract]. Pediatric Pulmonology 2000;Suppl 20:125-6.
46. Suri R, Wallis C, Bush A, Thompson S, Normand C, Flather M, et al. A comparative study of hypertonic saline, daily and alternate-day rhDNase in children with cystic fibrosis. Health Technology Assessment 2002; Vol. 34, issue iii:1-60.
47. Suri R, Wallis C, Metcalfe C, Thompson S, Bush A, Shute J. Effects of rhDNase and hypertonic saline on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology 2001;Suppl 22:281.
48. Suri R, Metcalfe C, Wallis C, Bush A. Assessing the usefulness of outcomes measured in a cystic fibrosis treatment trial. Respiratory Medicine 2007;101(2):254-60.
49. Vanlaethem S, Van Ginderdeuren F, Eyns H, Malfroot A. Influence of inhaled hypertonic saline combined with airway clearance on SpO2, heart rate, dyspnoea and wet sputum weight in hospitalised CF patients [abstract]. Journal of Cystic Fibrosis 2008;7(Suppl 2):S71.
50. Dentice R, Elkins MR, Bye PT. A randomised trial of the effect of timing of hypertonic saline inhalation in relation to airway clearance physiotherapy in adults with cystic fibrosis [abstract]. Pediatric Pulmonology 2010;Suppl 33:384.
51. Bateman JR, Pavia D, Clark SW. The retention of lung secretions during the night in normal subjects. Clinical Science and Molecular Medicine. Supplement 1978;55(6):523-7.
52. Buzzetti R, Salvatore D, Baldo E, Forneris MP, Lucidi V, Manunza D, et al. An overview of international literature from cystic fibrosis registries: 1. Mortality and survival studies in cystic fibrosis. Journal of Cystic Fibrosis 2009;8(4):229-37.
53. Cutting GR. Cystic fibrosis. In: Rimon DL, Connor JM, Pyeritz RE, Korf BR editor(s). Principles and Practice of Medical Genetics. 4th Edition. London: Harcourt, 2002:1561-606.
54. de Morton NA. The PEDro scale is a valid measure of the methodological quality of clinical trials: a demographic study. Australian Journal of Physiotherapy 2009;55(2):129-33.
55. Dentice R, Elkins M. Timing of dornase alfa inhalation for cystic fibrosis. Cochrane Database of Systematic Reviews 2011, Issue 5. [DOI: 10.1002/14651858.CD007923]
56. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
57. Elkins M, Jones A, van der Schans CP. Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD003147.pub3]
58. Elkins MR, Bye PT. Inhaled hypertonic saline as a therapy for cystic fibrosis. Current Opinion in Pulmonary Medicine 2006;12(6):445-52.
59. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
60. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
61. King M, Dasgupta B, Tomkiewicz RP, Brown NE. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease. American Journal of Respiratory and Critical Care Medicine 1997;156(1):173-7.
62. Maher CG, Sherrington C, Herbert RD, Moseley AM, Elkins M. Reliability of the PEDro Scale for Rating Quality of Randomized Controlled Trials. Physical Therapy 2003;83(8):713-21.
63. Main E, Prasad A, van der Schans CP. Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD002011.pub2]
64. Morrison L, Agnew J. Oscillating devices for airway clearance in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD006842.pub2]
65. Robinson KA, Mckoy N, Saldanha I, Odelola OA. Active cycle of breathing technique for cystic fibrosis. Cochrane Database of Systematic Reviews 2010, Issue 11. [DOI: 10.1002/14651858.CD007862.pub2]
66. van der Schans CP, Prasad A, Main E. Chest physiotherapy compared to no chest physiotherapy for cystic fibrosis. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD001401]
67. Wark PAB, McDonald VM. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database of Systematic Reviews 2010, Issue 3. [DOI: 10.1002/14651858.CD001506.pub3]
68. Wills PJ, Hall RL, Chan W, Cole PJ. Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucus-depleted bovine trachea. Journal of Clinical Investigation 1997;99(1):9-13.
69. WolffRK, Dolovich MB, Obminski G, Newhouse MT. Effects of exercise and eucapnic hyperventilation on bronchial clearance in man. Journal of Applied Physiology: Respiratory, Environmental and Exercise Physiology 1977;43(1):46-50.